Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*02 Disease Controlled Advanced Non-small Cell Lung Cancer

The purpose of this study is to evaluate the safety, tolerability, immune response and clinical efficacies of HLA-A*0201 restricted epitope peptides URLC10 emulsified with Montanide ISA 51 for disease controlled advanced non-small cell lung cancers.

The investigators previously identified a novel HLA-A*0201-restricted epitope peptide, which was derived from a cancer-testis antigen, URLC10 as a target for cancer vaccination against lung cancer. In this phase I/II trial, the investigators examine using the peptides the safety, immunogenicity, and antitumor effect of vaccine treatment for HLA-A*0201-positive advanced non-small cell lung cancer patients whose disease are controlled after any standard therapies, but who do not have any options for additional standard ones to prevent .future relapse of the disease.

Inclusion criteria

• NSCLC whose disease are controlled after any standard therapies, but who do not have any additional standard ones to prevent .future relapse of the disease.
• ECOG performance status 0-2
• Age between 20 to 85
• Clinical efficacy can be evaluated by some methods
• No prior chemotherapy, radiation therapy, hyperthermia or immunotherapy within appropriate periods
• Life expectancy > 3 months
• Laboratory values as follows 1500/mm3 < WBC < 15000/mm3 Platelet count > 75000/mm3 Asparate transaminase < 3 X cutoff value Alanine transaminase < 3 X cutoff value Total bilirubin < 3 X cutoff value Serum creatinine < 2X cutoff value
• HLA-A*0201
• Able and willing to give valid written informed consent

Exclusion criteria

• Active and uncontrolled cardiac disease (i.e. coronary syndromes, arrhythmia)
• Myocardial infarction within six months before entry
• Breastfeeding and Pregnancy (woman of child bearing potential)
• Active and uncontrolled infectious disease
• Concurrent treatment with steroids or immunosuppressing agent
• Other malignancy requiring treatment
• Non-cured traumatic wound
• Decision of unsuitableness by principal investigator or physician-in-charge